TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 294 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q1 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,435,326 | -61.4% | 286,705 | -60.8% | 0.01% | -71.4% |
| Q2 2023 | $11,494,347 | +107.0% | 731,658 | +117.2% | 0.04% | +75.0% |
| Q1 2023 | $5,552,063 | +77.6% | 336,897 | +54.3% | 0.02% | -7.7% |
| Q1 2022 | $3,126,000 | +13.3% | 218,322 | +7.8% | 0.03% | +23.8% |
| Q4 2021 | $2,759,000 | -13.6% | 202,448 | +3.8% | 0.02% | -47.5% |
| Q3 2021 | $3,195,000 | -7.3% | 195,080 | +3.4% | 0.04% | -27.3% |
| Q1 2021 | $3,446,000 | -4.5% | 188,713 | -4.8% | 0.06% | +7.8% |
| Q4 2020 | $3,609,000 | -57.8% | 198,311 | -58.6% | 0.05% | -58.2% |
| Q3 2020 | $8,544,000 | +276.7% | 478,899 | +278.5% | 0.12% | +269.7% |
| Q2 2020 | $2,268,000 | +21.7% | 126,510 | +34.0% | 0.03% | -43.1% |
| Q4 2019 | $1,863,000 | +262.5% | 94,412 | +215.9% | 0.06% | -83.0% |
| Q3 2019 | $514,000 | -11.5% | 29,887 | -8.9% | 0.34% | +147.8% |
| Q2 2019 | $581,000 | -50.2% | 32,800 | -52.7% | 0.14% | -72.6% |
| Q4 2018 | $1,166,000 | – | 69,304 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 7,584,930 | $138,046,000 | 26.79% |
| Glenview Capital Management | 15,260,512 | $277,741,000 | 6.37% |
| Paulson & Co. | 11,295,846 | $205,584,000 | 5.34% |
| GMT CAPITAL CORP | 2,871,395 | $52,259,000 | 3.72% |
| MANAGED ASSET PORTFOLIOS, LLC | 966,643 | $17,593,000 | 3.09% |
| TFG Asset Management GP Ltd | 1,443,052 | $26,264,000 | 1.76% |
| Mondrian Investment Partners LTD | 3,274,660 | $58,944,000 | 1.46% |
| Blackcrane Capital, LLC | 35,236 | $641,000 | 1.26% |
| Lumbard & Kellner, LLC | 136,378 | $2,404,000 | 0.95% |
| DAVIDSON INVESTMENT ADVISORS | 509,800 | $9,278,000 | 0.86% |